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December 8, 2009:2337–41For the reasons mentioned in the preceding text, coronary
ngiography can identify a higher rate of defective grafts compared
ith TTFM (3). The rate of graft revision based on TTFM is
etween 1% to 8% (2). These rates are well below the average 20%
o 30% 1-year saphenous vein graft (SVG) failure rate reported in
he literature (2,4). The PREVENT IV (PRoject of Ex-vivo Vein
raft ENgineering via Transfection IV) trial, a multicenter ran-
omized study of 3,041 patients, has confirmed the clinical impact
f vein graft failure. In this study, the common end point of death
nd new myocardial infarction was 0.9% in patients with patent
VG, while for patients with at least 1 occluded SVG this adverse
utcome was 14% (p  0.001) (4).
In order to improve the long-term outcomes of CABG surgery,
raft patency is a key factor. Grafts fail early primarily because of
echnical errors that could be corrected at the time of the surgery.
hile the TTFM and other techniques such as intraoperative
uorescence imaging are steps toward improving graft patency,
hey can identify only a limited number of graft defects, mostly
cclusive abnormalities, and cannot reliably identify significant
50%) nonocclusive graft flow abnormalities. These significant
raft abnormalities have important clinical impact on the long-
erm benefits provided by CABG surgery. For the reasons men-
ioned in the preceding text, routine angiography after CABG has
ow periprocedural morbidity. It seems that it should perhaps
ventually be routine if available in a hybrid suite.
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he SoS Acronym
he term “acronym” has been used since World War II. It referso an abbreviation created from the first letters of each word in a oeries of words. Typical examples are NATO (North Atlantic
reaty Organization) and SOS (Save our Souls).
Acronyms are frequently being used to refer to clinical trials,
ften with some difficulty. Occasionally even the PI (Primary
nvestigator) cannot remember the background of such
bbreviations.
In 1995 we embarked in a clinical trial comparing 2 treatment
ptions for myocardial revascularization, the use of stents versus
urgery. We simply called the trial SoS (Stent or Surgery) (1). The
esults of this trial have been published in leading journals, and the
tudy is still ongoing.
In the March 27, 2009, issue of the Journal (2), another SOS
rial was published. The authors decided to use the same, previ-
usly employed acronym to describe a comparison of different
tents for the treatment of saphenous vein grafts. The acronym
OS stands in this context for “a randomized controlled trial of a
aclitaxel-eluting stent versus a similar bare-metal stent in saphe-
ous vein graft lesions: the SOS (Stenting of Saphenous vein grafts
rial);” the association, apart from the infringement with previous
nd future SOS publications, seems far-fetched.
Even in the absence of legal guidelines, the reutilization of
stablished acronyms (in particular, if they are still in use) should
e discouraged. Authors and editors ought to adopt some common
ense to avoid confusion.
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eply
cronyms are an important component of clinical trials and may
erve several roles, such as facilitating reference to the trial, creating
nthusiasm about the trial, and promoting recruitment. SOS is a
rief and memorable acronym that is particularly well suited for
rials, as it invokes a call for help to which many patients might
espond. Indeed, SOS is a widely used trial acronym: a search for
OS in the clinical trials website on July 13, 2009, retrieved 28
esults, ranging from the “Stent or Surgery” trial (NCT00475449)
o “Systems of Support to Increase Colon Cancer Screening
nd Follow-up” (NCT00697047) to “Stroke Oxygen study”
ISRCTN52416964) or the “SAFE OR SORRY?” trial
NCT00365430).
In 1987, the Swedish Obese Subjects study was initiated, and
ver the ensuing 2 decades it critically evaluated the effects of
